Navigation Links
Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
Date:12/8/2008

from the AEGIS study in an application for marketing authorization to be submitted to the PMDA in 2009. The Company has begun to establish its commercial organization in Japan in anticipation of a commercial launch of Soliris in that country in 2010.

About PNH

PNH is a rare blood disorder that affects an estimated 8,000 to 10,000 people in North America and Europe and, using similar prevalence estimates, potentially 1,000 - 2,000 patients in Japan. (4) PNH strikes people of all ages, with an average age of onset in the early 30s. (5) Approximately 10 percent of all patients first develop symptoms at 21 years of age or younger. (6) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis ranging from one to more than 10 years. (7) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis. (5,7)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndromes (MDS). (8,9,10) In patients with thrombosis of unknown origin, PNH may be an underlying cause. (6,11)

Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk. (6,11)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commission (EC) also approved the use of Soliris for the treatment of patients with PNH.
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
2. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
6. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
7. GEN Reports on the Trend Toward Predictive Toxicogenomics
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SEOUL, South Korea , Aug. 28, 2015 /PRNewswire/ ... Chungbuk National University and Dr. Ra from Biostar ... , Confirmed 30% increase of lifespan through multiple ... cognitive function, physical vitality, and life expectancy found ... Researchers in Korea have determined the possibility that adult ...
(Date:8/27/2015)... , Aug. 27, 2015  The Academy of ... and Drug Administration,s (FDA,s) draft guidance and proposed ... and biosimilars, to bear a nonproprietary name with ... been seeking a decision from the FDA on ... health care stakeholders urging the agency to use ...
(Date:8/27/2015)... -- According to a new market research report "Medical ... Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End ... the Medical Lifting Sling Market is poised to reach USD 706.0 ... CAGR of 11.4 % from 2015 to 2020. ... T ables and 65 F ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2011 Hurricane Irene came rushing up the East Coast as ... the United States, many states in the Northeast began to worry. ... to hurricanes. Coastal towns from New Jersey all the way up ... York City was one that took steps that had not been ...
... DIEGO, Aug. 30, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE ... on its planned meetings with the U.S. Food and ... Exelbine (vinorelbine injectable emulsion) Type ... is to discuss the complete response letter regarding the ...
Cached Medicine Technology:Hospitals Evacuated in Preparation for Hurricane Irene with Aid of Pulse Oximeter 2ADVENTRX Provides Update on All Three Pipeline Products 2ADVENTRX Provides Update on All Three Pipeline Products 3ADVENTRX Provides Update on All Three Pipeline Products 4
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the City, ... added yet another accolade to its cadre of widespread support—an official letter of support ... help of the medical community and the University of Illinois at Chicago’s Department of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs and ... James Strawbridge, gives a new approach on solutions in his new book ":Unraveling ... employer and employees getting together for meaningful group meetings. "This would educate the ...
(Date:8/28/2015)... ... 28, 2015 , ... CARF International announced that West Ridge ... treatment and intensive family based services. , By pursuing and achieving accreditation, West ... of excellence. As a nonprofit charity for more than 50 years, West Ridge ...
(Date:8/28/2015)... Rochester, NY (PRWEB) , ... August 28, 2015 , ... ... injectable, Kybella™. It is the first and only nonsurgical product approved by the ... Dr. Vito Quatela and Dr. William Koenig are among ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... News) -- A growing number of Americans are getting advice ... rather than friends, a new survey indicates. About ... media such as Facebook and Twitter, a substantial increase from ... who sought information from friends fell from 63 percent in ...
... Moffitt Cancer Center in Tampa, Fla., have discovered that ... roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens ... The study was published in a recent issue ... identified oconogene, a gene linked to cancer," said study ...
... BOSTON (2-8-12) Observing that certain cancer cells may ... that this capability promotes rapid tumor growth. Now computer ... Muhammad Zaman and collaborators at the University of Texas ... model of healthy and cancer cells that they,ve created ...
... In a study to be presented today at the ... , in Dallas, Texas, researchers will report findings that ... section appear to know little about the risks and ... trial of labor to attempt a vaginal delivery, and ...
... TAMPA, Fla. and ORLANDO, Fla. Moffitt Cancer ... have announced they will collaborate on the creation ... Florida). The partnership will conduct collaborative research to ... areas of cancer and metabolic diseases, including obesity, ...
... supports an association between atypical fractures of the femur a ... and the use of bisphosphonates, drugs proven to enhance bone ... risk for suffering an atypical femur fracture while taking bisphosphonates ... after six years of treatment research presented today at ...
Cached Medicine News:Health News:More Patients Seek Plastic Surgery Advice From Facebook, Twitter 2Health News:Researchers find important 'target' playing role in tobacco-related lung cancers 2Health News:Boston University research suggests new pathways for cancer progression 2Health News:Study finds pregnant women with prior cesarean choose the delivery method preferred by their doctor 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 3Health News:Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half 2
Denman brown nucleus cracker with 30 angled shafts, tip to angle length 14.5 mm. Standard cross action handle. 1.1 mm x 1.2 mm paddle style tips....
Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
Epilation forceps straight ends size 3.5"....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Medicine Products: